Department of Clinical Laboratory, Binhai County People's Hospital, Jiangsu, China.
Department of Medical Oncology, Binhai County People's Hospital, Jiangsu, China.
Yonsei Med J. 2020 Jan;61(1):15-19. doi: 10.3349/ymj.2020.61.1.15.
The purpose of this study was to assess the diagnostic and prognostic value of serum progastrin-releasing peptide (ProGRP) in patients with gastric cancer (GC).
A total of 150 patients with GC (89 males and 61 females) were recruited, including those with stage I (n=28), stage II (n=33), stage III (n=50), and stage IV (n=39) disease; 50 healthy controls and 66 patients with benign gastric diseases were also enrolled. Levels of serum ProGRP, carcinoembryonic antigen (CEA), and carbohydrate antigen 72-4 (CA72-4) were measured in all subjects.
Serum ProGRP levels were significantly higher in GC patients than in controls (<0.001), and ProGRP was significantly correlated with tumor size, tumor node metastasis stage, differentiation, invasion depth, and lymph node metastasis (< 0.005). ProGRP levels were significantly decreased after chemotherapy (<0.001). Receiver operating characteristic curves revealed a sensitivity and specificity for serum ProGRP in GC of 85.9% and 81.2%, respectively. ProGRP levels were positively correlated with CA72-4 and CEA (r=0.792 and 0.688, <0.05, respectively). Combined detection of ProGRP, CEA, and CA72-4 showed the best diagnostic power for GC.
ProGRP may be useful as a potential biomarker for GC diagnosis and therapy.
本研究旨在评估血清胃泌素释放肽前体（ProGRP）在胃癌（GC）患者中的诊断和预后价值。
共招募了 150 例 GC 患者（男性 89 例，女性 61 例），包括Ⅰ期（n=28）、Ⅱ期（n=33）、Ⅲ期（n=50）和Ⅳ期（n=39）患者；同时还招募了 50 名健康对照者和 66 名良性胃部疾病患者。所有受试者均测量血清 ProGRP、癌胚抗原（CEA）和糖类抗原 72-4（CA72-4）水平。
GC 患者的血清 ProGRP 水平明显高于对照组（<0.001），ProGRP 与肿瘤大小、肿瘤淋巴结转移分期、分化程度、浸润深度和淋巴结转移明显相关（<0.005）。化疗后 ProGRP 水平显著降低（<0.001）。受试者工作特征曲线显示血清 ProGRP 对 GC 的敏感性和特异性分别为 85.9%和 81.2%。ProGRP 水平与 CA72-4 和 CEA 呈正相关（r=0.792 和 0.688，<0.05）。ProGRP、CEA 和 CA72-4 的联合检测对 GC 具有最佳的诊断效能。
ProGRP 可能是 GC 诊断和治疗的有潜力的生物标志物。
